Grön Launches 1000mg BIG BAR Chocolates
The Mother of all Edibles Brings Massive Innovation to Missouri and Arizona Cannabis Markets With New Macro-Dose Value Friendly Large Format Chocolates
PORTLAND, Ore., March 05, 2025 (GLOBE NEWSWIRE) -- Grön (pronounced grewn), is bringing something big to the cannabis edibles market. Something really BIG! Grön, the fastest growing edibles brand and acclaimed woman-led producer of innovative, handcrafted cannabis-infused edibles, today announced the launch of its most potent and value-packed edible yet—the BIG BAR, a 1000mg THC Fair Trade Certified chocolate bar designed for experienced cannabis consumers and medical patients. As part of its continued effort to provide the highest quality products in forms and doses that match consumer demands Grön, is making the impressive BIG BAR in two delicious flavors, Dark Chocolate and Milk Chocolate - both made with ethically produced fair trade chocolate - exclusively for the Missouri adult-use and Arizona medical markets.
More THC. More Chocolate. More to Love.
The Grön BIG BAR is the latest innovation from the company known as The Mother of All Edibles, which first entered the cannabis edibles market selling handcrafted fair trade chocolates produced by Founder and CEO Christine Apple. Today Grön, is building upon its own legacy of excellence as a cannabis chocolatier with a large format chocolate bar crafted for those who demand maximum potency, indulgence, and value from their edibles. Infused with 1000mg of premium THC per BIG BAR, the new chocolate powerhouse provides a cost-effective option for high-tolerance consumers and patients who want the most THC per dollar—without compromising on flavor or quality. The BIG BAR, weighing 2.5 oz of chocolate, expands Grön's existing lineup, which includes the standard 1.6 oz Chocolate Bar and the 0.25 oz Mini Bar, available in Arizona and Missouri.
Dark Chocolate BIG BAR – Bold, rich, and deeply satisfying, made with Fair Trade cocoa for a luxuriously smooth experience and dusted with Jacobson Sea Salt.
Milk Chocolate BIG BAR – Creamy, velvety, and irresistibly indulgent, offering a melt-in-your-mouth taste with premium ethically sourced ingredients and dusted with Jacobson Sea Salt.
"We created the BIG BAR not just for its potency but because we know consumers and medical patients want more—more THC, more chocolate, and more value in their edibles," said Christine Apple, Founder and CEO of Grön. "This product delivers exactly that, combining high-dose THC with the same premium ingredients and cannabis extract that make Grön a trusted name in the market."
Where to Find the BIG BAR
Launching in March 2025, the BIG BAR will be available at Missouri adult-use cannabis retailers and Arizona medical dispensaries. As with all Grön products, the BIG BAR is gluten-free, soy-free, and made with ethically sourced ingredients, ensuring a consistent and premium edible experience.
Grön's BIG BAR will be available at select retailers throughout Missouri (https://eatgron.com/arizona/chocolate-milk-chocolate-big-bar-mo/) and Arizona (https://eatgron.com/arizona/chocolate-milk-chocolate-big-bar-az/). For more information about Grön visit: www.eatgron.com.
About Grön Grön is one of North America's largest producers of adult-use cannabis-infused edibles. Our passionate team of seasoned executives, chocolatiers, and confectioners come from all over the world and every walk of life, joining together to create something beautifully delicious for you. Our ingredients are organic, single-origin, Fair Trade Certified, and locally sourced whenever possible. Product offerings include Sugar-Coated Pearls, MEGAs, cannabis-infused chocolate, and Pips. Since inception, Grön has led the cannabis edibles category with a vast selection of expanding product lines. Though our foundation is artisan chocolate, product innovation continues to shape our offerings in markets hungry for something new. Grön cannabis edibles are available in Arizona, Missouri, New Jersey, New York, Ohio, Oregon, and across Canada, with multiple new markets added by the end of 2024. For more information, visit www.eatgron.com.
Media Contact Oak PRRaquel Heras Raquel@oakpr.com
Photos accompanying this announcement are available at:
https://www.globenewswire.com/NewsRoom/AttachmentNg/2bf979b9-925a-48ad-a285-376e2a87e506
https://www.globenewswire.com/NewsRoom/AttachmentNg/0ca76b15-5de6-4aa2-a1bd-8974ca23bad2Sign in to access your portfolio
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
28 minutes ago
- Yahoo
Cycurion Reports Financial Results for the First Quarter 2025
MCLEAN, Va., June 06, 2025 (GLOBE NEWSWIRE) -- Cycurion, Inc. (Nasdaq: CYCU) ('Cycurion' or the 'Company'), a trusted leader in IT cybersecurity solutions and AI, reports financial results for the first quarter ended March 31, 2025, and provides a corporate update. Financial Highlights Revenues of $3.9 million. Gross Profit of $677,673, up 95.4% year-over-year, with a 17.5% gross margin increase in the first quarter of 2025 compared to $346,714 (8.2% gross margin) in the first quarter of 2024, reflecting a focus on capturing and retaining more profitable business. Adjusted EBITDA of $245,062 (6.3% margin) in the first quarter of 2025 compared to $(68,803) in the first quarter of 2024, reflecting strong cost management coupled with both scalable operating leverage and an optimized service mix that included a higher proportion of enterprise clients and stronger government relationships, leading to a significant improvement in adjusted EBITDA in the first quarter of 2025. Net loss of $(10.2) million, consisting of $9.3 million in non-recurring pre-tax charges of non-cash stock compensation expenses and $1.2 million in merger-related expenses, compared to $(0.3) net loss in the first quarter of 2024. Net loss per share of $(0.56) basic and fully diluted that included the aforementioned non-recurring significant pre-tax charges, compared to $(0.02) in the first quarter of 2024. Q1 2025 and Recent Strategic, Technological and Corporate Milestones Listed and Began Trading on Nasdaq: Completed a business combination with Western Acquisition Ventures Corp. in February 2025 and had its shares of common stock listed on the Nasdaq Global Select Market. Broader Rollout of AI-driven SaaS ARx Cybersecurity Platform: High margin, AI-driven cybersecurity solutions have been instrumental in driving margin expansion, enhancing operational scale and strengthening Cycurion's market position, offering advanced capabilities to a wider array of clients. Strategic Partnerships Delivering Results: Long-term partnerships forged in both the public and private sectors are beginning to yield tangible revenue-generating opportunities. These collaborations validate Cycurion's go-to-market strategy and enhance its credibility within the industry. Notably, partnerships have already resulted positively. Includes SOC as Service, External Attack Surface Management, Web Application Firewall and Virtual CISO Support & Consulting. Backlog Reaching Record Levels: Witnessing a robust increase in its backlog of contracted work, which has reached record levels the first quarter of 2025, reflecting strong client demand for Cycurion's scalable solutions, indicating a positive outlook for future revenue streams. New Contracts: Secured a $22 million multi-year contract with State Police Agency. Management CommentaryKevin Kelly, Cycurion CEO, stated, 'As we look ahead, we remain optimistic about the continued demand for our high-margin services and innovative solutions. The company is committed to leveraging the growing client backlog and the success of the ARx platform to drive further growth. Additionally, our focus on nurturing strategic partnerships will be crucial in expanding our market presence and creating new revenue opportunities. Cycurion is poised for a strong 2025, driven by a strategic overhaul focused on sustainable growth and innovation. Over the past year, the company streamlined operations, significantly cutting General and Administrative (G&A) expenses while boosting gross profit for greater financial strength. We have invested heavily in AI-driven technology, sharpening its competitive edge. By pivoting away from low-margin clients to high-value opportunities, the Company has built a robust framework for organic growth while paving the way for expansion, entering 2025 with clear momentum and vision.' About CycurionBased in McLean, Virginia, Cycurion (Nasdaq: CYCU) is a forward-thinking provider of IT cybersecurity solutions and AI, committed to delivering secure, reliable, and innovative services to clients worldwide. Specializing in cybersecurity, program management, and business continuity, Cycurion harnesses its AI-enhanced ARx platform and expert team to empower clients and safeguard their operations. Along with its subsidiaries, Axxum Technologies LLC, Cloudburst Security LLC, and Cycurion Innovation, Inc., Cycurion serves government, healthcare and corporate clients with a commitment to securing the digital future. Forward Looking StatementsThis press release contains statements that are forward-looking statements as defined within the Private Securities Litigation Reform Act of 1995, including, but not limited to, statements relating to the operations and prospective growth of Cycurion's business. Many factors could cause Cycurion's actual results, performance, or achievements to be materially different from any future results, performance, or achievements described in this press release, including words such as 'continue', 'expect', 'intend', 'will', 'hope', 'should', 'would', 'may', 'potential', and other similar expressions. Such factors could include, among others, those detailed in its Registration Statement on Form S-1 and in its Annual Report on Form 10-K, each as filed with the Securities and Exchange Commission (the 'SEC'). Should one or more of these risks or uncertainties materialize, or should the assumptions set out in the section entitled 'Risk Factors' in those filings with the SEC underlying those forward-looking statements prove incorrect, actual results may vary materially from those described herein. These forward-looking statements are made as of the date of this press release and Cycurion does not intend, and does not assume any obligation, to update these forward-looking statements, except as required by law. Cycurion cannot assure that such statements will prove to be accurate as actual results, and future events could differ materially from those anticipated in such statements. Individuals are cautioned that forward-looking statements are not guarantees of future performance and, accordingly, investors are cautioned not to put undue reliance on forward-looking statements due to the inherent uncertainty therein. Investor Contact:CORE IRinvestors@ Media Contact:Phone: (703) 555-0123Email: media@ Non-GAAP Financial MeasuresStatements in this release include financial information presented in accordance with accounting principles generally accepted in the United States ("GAAP") and also include non-GAAP financial measures that are provided as additional information to enhance the overall understanding of the Company's current financial performance and not as an alternative to the consolidated interim financial statements presented in accordance with GAAP. Management uses these non-GAAP measures (earnings before interest, taxes, depreciation, and amortization ("EBITDA"), Adjusted EBITDA, Adjusted EBITDA margin, Free Cash Flow) to evaluate the Company's financial performance. These terms might not be calculated in the same manner as, and thus might not be comparable to, similarly titled measures reported by other companies. The financial information tables that accompany this press release include reconciliations of net income to non-GAAP financial measures. EBITDA, Adjusted EBITDA and Adjusted EBITDA margin provide a measure of the Company's operating results in a manner that is focused on the performance of the Company's core business on an ongoing basis, by removing the effects of non-operating and certain non-cash expenses. These non-operating and non-cash items are specifically identified in the reconciliations of GAAP measures to non-GAAP measures that accompany this release. Free Cash Flow provides useful information to investors about the amount of cash generated by the business that can be used for strategic opportunities and is computed as Cash Flows from Operating Activities less both the Purchase of Property and Equipment & Purchase of Intangible Assets. CYCURION, INC. AND ITS SUBSIDIARIESRECONCILIATION OF GAPP TO NON-GAAP MEASURES (Unaudited) Quarter ended March 31, 2025 2024 Net income (loss) $ (10,248,486 ) $ (312,475 ) Provision for income taxes - - Interest expense 178,890 231,475 Depreciation of fixed assets 1,709 2,197 Amortization of software development costs 8,333 - Gain on settlement of debt (141,653 ) - EBITDA (non-GAAP measure) $ (10,201,207 ) $ (78,803 ) Stock compensation expense 9,250,000 10,000 Merger-related expense 1,196,269 - Adjusted EBITDA (non-GAAP measure) $ 245,062 $ (68,803 )Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
33 minutes ago
- Yahoo
Sagteс Ignites AI Commercialization Surge with US$5 Million in Contracts, Targeting US$50 Million Pipeline in 12 Months
Breakthrough Robotics and CRM Deployments Set Stage for Scalable Recurring Revenue Across Southeast Asia and Hong Kong KUALA LUMPUR, Malaysia, June 06, 2025 (GLOBE NEWSWIRE) -- Sagtec Global Limited (NASDAQ: SAGT) ('Sagtec' or the 'Company'), the next-generation provider of customizable AI and automation platforms, today announced the signing of two major commercial contracts totaling US$5 million less than one week after the official launch of its AI-powered robotics platform. These early wins underscore an accelerated go-to-market approach and build momentum toward a commercial pipeline exceeding US$50 million over the next 12 months. This positions Sagtec as a rising leader in AI automation across the Asia-Pacific region. Key Highlights: US$2 Million Robotics Deployment Sagtec will deploy over 100 autonomous robotic units to a leading multi-brand restaurant group in Malaysia. This marks the initial phase of a nationwide rollout, expected to generate more than US$20 million in cumulative revenue over the next year under a Robotics-as-a-Service (RaaS) model. US$3 Million CRM Platform Contract The Company also secured a significant Customer Relationship Management (CRM) project with a prominent F&B operator. The solution features modules for loyalty management, points and credits tracking, inventory control, and workforce administration. This contract is projected to add over US$30 million in Software-as-a-Service (SaaS) revenue pipeline through regional expansion. Both contracts are powered by Sagtec's modular, full-stack AI platform, which integrates voice-activated robotics, POS systems, and real-time analytics. These milestone deployments validate Sagtec's dual-engine monetization strategy across RaaS and SaaS, generating scalable, high-margin recurring revenue. Strategic Outlook: With demand for automation accelerating in high-volume service sectors, Sagtec is actively expanding commercial engagements across Southeast Asia, Hong Kong, and the Gulf Cooperation Council (GCC) markets. The global service robotics market is projected to surpass US$90 billion, and Sagtec is strategically positioned to lead as a platform-native AI solution provider at scale. Momentum Metrics – Past 7 Days • 2 contracts signed worth US$5M • 100+ robotic units deployed • Targeting US$50M revenue pipeline • Enterprise client base expansion across 3 regions • New verticals in hospitality, retail, and foodtech unlocked 'This is more than early traction. It marks the beginning of an exponential monetization curve. Our combined RaaS and SaaS model is engineered for rapid scaling with enterprise adoption. By embedding AI directly into day-to-day operations, we are unlocking repeatable revenue at the infrastructure level, from robotics to real-time CRM analytics,' said Kevin Ng, Chairman, Executive Director, and Chief Executive Officer of Sagtec. About Sagtec Global Limited Sagtec is a leading provider of customizable software solutions, primarily serving the Food & Beverage (F&B) sector. The Company also offers software development, data management, and social media management to enhance operational efficiency across various industries. Additionally, Sagtec operates power-bank charging stations at 300 locations across Malaysia through its subsidiary, CL Technology (International) Sdn Bhd. For more information on the Company, please log on to Contact Information: Sagtec Global Limited Contact:Ng Chen LokChairman, Executive Director & Chief Executive OfficerPhone: +6011-6217 3661Email: info@ in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
37 minutes ago
- Yahoo
Heidelberg Pharma to Present at the Life Sciences Virtual Investor Forum June 12th
Heidelberg Pharma invites individual and institutional investors, as well as advisors and analysts, to attend online at LADENBURG, Germany, June 06, 2025 (GLOBE NEWSWIRE) -- Heidelberg Pharma AG (XETRA: HPHA), a clinical-stage biotech company developing innovative Antibody Drug Conjugates (ADCs), today announced that Andreas Pahl, CEO of Heidelberg Pharma, will present live at the Life Sciences Virtual Investor Forum hosted by on June 12th, 2025. Heidelberg Pharma's lead candidate, HDP-101, a BCMA-targeting ADC with the novel payload Amanitin, is being evaluated in a Phase I/IIa clinical trial for the treatment of relapsed or refractory Multiple Myeloma. HDP-101 is showing promising results, including a prolonged complete response in a patient who had undergone extensive prior treatment. The patient has received continuous treatment with HDP-101 alone for over 19 months, showing excellent tolerability of the drug. In addition, promising biological activity and objective improvements were observed in several patients, underscoring the potential of HDP-101 as a treatment option for Multiple Myeloma. Dose escalation is continuing, and the study is advancing in cohort 8. Furthermore, the second candidate, HDP-102, a CD-37-targeting ADC with the novel payload Amanitin, has recently entered clinical development and the first patient has been dosed in a Phase I study for the treatment of non-Hodgkin lymphoma (NHL). DATE: June 12th TIME: 10:00 AM ETLINK: REGISTER HEREAvailable for 1x1 meetings: June 12th and 13th This will be a live, interactive online event where investors are invited to ask the company questions in real-time. If attendees are not able to join the event live on the day of the conference, an archived webcast will also be made available after the event. It is recommended that online investors pre-register and run the online system check to expedite participation and receive event updates. Learn more about the event at Recent Company Highlights Heidelberg Pharma Announced First Patient Dosed in Phase I Study of Amanitin-based ADC Candidate HDP-102 for Non-Hodgkin Lymphoma Heidelberg Pharma to Present Promising New Clinical Data on its Lead ATAC Candidate HDP-101 at EHA 2025 PR: Heidelberg Pharma Amended Royalty Financing with HealthCare Royalty About Heidelberg Pharma Heidelberg Pharma is a biopharmaceutical company working on a new treatment approach in oncology and developing novel drugs based on its ADC technologies for the targeted and highly effective treatment of cancer. ADCs are antibody-drug conjugates that combine the specificity of antibodies with the efficacy of toxins to fight cancer. Selected antibodies are loaded with cytotoxic compounds, the so-called payloads, that are transported into diseased cells. Inside the cells, the toxins then unleash their effect and kill the diseased cells. Heidelberg Pharma uses several compounds and has built up an ADC toolbox that overcomes tumor resistance via numerous pathways and addresses different types of cancer using various antibodies. The goal is to develop targeted and highly effective ADCs for the treatment of a variety of malignant hematologic and solid tumors. Heidelberg Pharma is the first company to use the compound Amanitin from the green death cap mushroom in cancer therapy. The biological mechanism of action of the toxin represents a new therapeutic modality and is used as a compound in the Amanitin-based ADC technology, the so-called ATAC technology. The company is based in Ladenburg, Germany, and is listed on the Frankfurt Stock Exchange: ISIN DE000A11QVV0 / WKN A11QVV / Symbol HPHA. More information is available at ATAC® is a registered trademark of Heidelberg Pharma Research GmbH. ITAC™, ETAC™ are pending trademark applications of Heidelberg Pharma Research GmbH. About Virtual Investor Conferences®Virtual Investor Conferences (VIC) is the leading proprietary investor conference series that provides an interactive forum for publicly traded companies to seamlessly present directly to investors. Providing a real-time investor engagement solution, VIC is specifically designed to offer companies more efficient investor access. Replicating the components of an on-site investor conference, VIC offers companies enhanced capabilities to connect with investors, schedule targeted one-on-one meetings and enhance their presentations with dynamic video content. Accelerating the next level of investor engagement, Virtual Investor Conferences delivers leading investor communications to a global network of retail and institutional investors. CONTACTS:Heidelberg Pharma AG Sylvia Wimmer Director Corporate CommunicationsTel.: +49 89 41 31 38-29E-mail: investors@ Gregor-Mendel-Str. 22, 68526 Ladenburg Virtual Investor Conferences John M. ViglottiSVP Corporate Services, Investor AccessOTC Markets Group (212) 220-2221johnv@ in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
